BCTX vs BDRX

BriaCell Therapeutics Corp. vs Biodexa Pharmaceuticals plc — Valuation Comparison 2026

BCTX

Biotechnology
BriaCell Therapeutics Corp.
Quality
4.5
out of 10
Value Trap
24
SAFE
Price
$3.58
Last close
Models
7/13
Active
VS

BDRX

Biotechnology
Biodexa Pharmaceuticals plc
Quality
1.7
out of 10
Value Trap
Price
$3.36
Last close
Models
6/13
Active

Model-by-Model Comparison

ModelType BCTX Fair ValueBCTX Upside BDRX Fair ValueBDRX Upside
Bayesian DCF Intrinsic $3.26 -8.9% $0.89 -73.5%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.38 -91.0% $3.04 -7.9%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for BCTX vs BDRX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

BCTX vs BDRX — Which Stock Is More Undervalued?

BCTX scores higher with a 4.5/10 quality rating vs BDRX's 1.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing BriaCell Therapeutics Corp. (BCTX) and Biodexa Pharmaceuticals plc (BDRX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

BCTX currently trades at $3.58 with a QOC of 4.5/10, while BDRX trades at $3.36 with a QOC of 1.7/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).